Alterations in maternal-fetal cellular trafficking after fetal surgery

Division of Pediatric Surgery and Fetal Treatment Center, Department of Surgery, University of California, San Francisco, CA 94143-0570, USA.
Journal of Pediatric Surgery (Impact Factor: 1.31). 06/2012; 47(6):1089-94. DOI: 10.1016/j.jpedsurg.2012.03.012
Source: PubMed

ABSTRACT Bidirectional trafficking of cells between the mother and the fetus is routine in pregnancy and a component of maternal-fetal tolerance. Changes in fetal-to-maternal cellular trafficking have been reported in prenatal complications, but maternal-to-fetal trafficking has never been studied in the context of fetal intervention. We hypothesized that patients undergoing open fetal surgery would have altered maternal-fetal cellular trafficking.
Cellular trafficking was analyzed in patients with myelomeningocele (MMC) who underwent open fetal surgical repair (n = 5), patients with MMC who had routine postnatal repair (n = 6), and healthy control healthy patients (n = 9). As an additional control for the fetal operation, trafficking was also analyzed in patients who were delivered by an ex utero intrapartum treatment procedure (n = 6). Microchimerism in maternal and cord blood was determined using quantitative real-time polymerase chain reaction for nonshared alleles.
Maternal-to-fetal trafficking was significantly increased in patients who underwent open fetal surgery for MMC compared with healthy controls, patients who underwent postnatal MMC repair, and patients who underwent ex utero intrapartum treatment. There were no differences in fetal-to-maternal cell trafficking among groups.
Patients undergoing open fetal surgery for MMC have elevated levels of maternal microchimerism. These results suggest altered trafficking and/or increased proliferation of maternal cells in fetal blood and may have important implications for preterm labor.


Available from: Michael P Busch, May 11, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The improvements in fetal diagnosis or imaging, maternal-fetal anaesthesia, and instrumenta-tion have resulted in a wider application of fetal surgery for complex fetal diseases of the fetal patient in order to prevent death and to improve the quality of life for long-term survivors. However, for all decisions the maternal risks have to be balanced and considered in the informed consent process. Sometimes symptoms of the fetal disease may overlap with risks of the procedures. Maternal symptoms may even improve after fetal surgery in some cases. Here we aim at illustrating the short- and long-term consequences of different procedures of fetal surgery in order to improve the indication and informed consent process with the parents. Interdisciplinary team approaches help to illustrate the fetal, neonatal and maternal consequences when discussing and indicating fetal surgery and hopefully facilitate a long-term support for the family.
    Zeitschrift für Geburtshilfe und Neonatologie 04/2014; 218(2):64-73. DOI:10.1055/s-0034-1368787 · 0.46 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Maternal-fetal cellular trafficking (MFCT) is the bidirectional passage of cells that results in the presence of fetal cells in the mother and maternal cells in the fetus. This naturally occurring biological phenomenon has been implicated in the pathogenesis of autoimmune diseases in both mothers and children. However, MFCT may also have beneficial consequences in establishing and maintaining maternal-fetal tolerance and may have long-term consequences for transplantation tolerance. There is also evidence that trafficking is altered during pregnancy complications and fetal intervention. An improved understanding of cellular trafficking during pregnancy will lead to progress in multiple fields including autoimmunity, transplantation, and fetal surgery.
    Seminars in Pediatric Surgery 02/2013; 22(1):62-5. DOI:10.1053/j.sempedsurg.2012.10.011 · 1.94 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Maternal-fetal cellular trafficking (MFCT) is the bidirectional passage of cells between mother and fetus during pregnancy. This results in the presence of fetal cells in the maternal circulation, known as fetal microchimerism, and maternal cells in the fetal circulation, known as maternal microchimerism. The biologic role of this transplacental cellular trafficking during pregnancy is not known, although it has been implicated in development of the fetal immune system, tolerance mechanisms during pregnancy, tissue repair in autoimmune disease and cancer, and immune surveillance. Clinical utility of MFCT has been identified in prenatal testing for aneuploidies and prediction of pregnancy complications. Additionally, this transplacental passage of cells has been implicated in the delicate balance between immunologic priming and tolerance, which can influence the occurrence of autoimmune disease and transplantation outcomes. Ongoing studies are evaluating the utility of microchimerism in predicting the risk of graft rejection in transplantation. In this review, we will discuss the clinical implications of MFCT in pregnancy, fetal surgery, autoimmune disease, transplantation, and cancer.
    Current opinion in pediatrics 04/2014; 26(3). DOI:10.1097/MOP.0000000000000087 · 2.74 Impact Factor